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Introduction:
Annual Report 1989

As Chairperson of the Cancer Committee, I
find myself continuously amazed at the growth
of our old programs and the development of
new programs in Oncology at St. Luke’s
Medical Center. This growth has come
because of a unique productive association of
the medical staff, hospital administration, and
community, which together has provided the
knowledge, financial resources, and motivation
to assure continued progress.
MaJCia J.S. Richards, M.D.
Our relationship with the Vince Lombardi
Golf Classic continues to financially help support basic research,
community education, and prevention and detection efforts. The
Cancer Information Hofline, physician newsletter, and screening
and early detection programs in numerous areas are but a portion
to which they contribute. Security Savings and Loan funds also
assist with physician education.
Each year our medical staff, with its expertise, adds new clinical
services and investigational therapies for our patients, which are
detailed later in this report. The community, medical staff, and
patients have recongnized their advances, and we find ourselves
providing Oncology Services to a larger portion of our community.
These efforts require a dedicated and motivated team of people
too numerous to mention. It is to them that credit should be
given, some of whom regularly receive recognition and many who
serve more quietly.
Indeed, together we had an exciting and productive year in which
many lives were affected in a positive and often life giving manner.
Lastly, the patients and their families provide us each day with
the last element for success motivation to achieve even greater
goals.
Marcia J.S. Richards, M.D.
Chairperson
-
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New Developments
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VNA hospice care, in conjunction with
St. Lukes Medical Center, offers a warn-i,
supportive alternative to patients who are
no longer receiving curative treatment.

VNA Community Hospice, a program of the
Visiting Nurse Association, is continuing to
provide Hospice care to patients and families
in the greater Milwaukee Area. Established in
conjunction with St. Luke’s Medical Center in
November, 1989, the program has served over
200 patients. As required of a MedicareCertified Hospice, well over 90% of this care
has been provided in the client’s home. The
remaining 10% has been provided inpatient
at St. Luke’s Methodist Manor, or one of the
additional inpatient contract facilities.
Hospice is primarily a concept of care rather
than a specific place. The main focus of this
care is symptom management in a setting
that is warm and supportive. Hospice is now
nationally recognized as an alternative to
traditional hospital care for patients who are
no longer receiving treatment for cure of their
disease.
The VNA Hospice Team is specially trained
to
help the terminally ill patient and family
Aileen Denny M.D.
tnrougn tne crisis perioa orr aeatn an
bereavement. Team members are available 24 hours a day, 7 days
a week. The team consists of physicians, nurses, counselors,
chaplain, social workers, therapists, aides, volunteers, the patient
and family. The patient’s plan of care is reviewed on a bi-weekly
basis with continual direction by the patient’s primary physician.
For more information regarding the Hospice Concept of Care,
contact Jackie Burdick, R.N. Manager, or Ann Patterson, RN.,
Hospice Cooridinator, at 327-2295.
Jackie Burdick, R.N.
VNA Community Hospice
Aileen Denny, M.D.
Medical Director
i
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Autologous bone marrow transplantation I
reinfusion (ABMR) is increasingly utilized as
treatment for certain patients with Hodgkin’s
and non-Hodgkin’s lymphoma, some leukemias,
and solid tumors such as breast cancer, who
have failed conventional therapy but have
chemosensitive tumors. ABMR takes advantage
of
the dose-response curve of chemotherapeutic
,r
agents and allows for the delivery of otherwise
marrow toxic doses of therapy, which are given
Kati7y Otdt,am, R. N.
in an attempt to produce long term remission,
and potentially “cure” patients with refractory
disease.
Patient accrual for ABMR at St. Luke’s Medical
Center began in March, 1990. Active protocols
include ABMR for the treatment of patients
with Hodgkin’s and non-Hodgkin’s lymphoma
and early recurrent breast cancer. Also, patients
in remission can have their marrow or stem
cells collected and stored for later use should
their disease reoccur. Eight patients have been
treated since March, three patients with
Robert Tayloi M.D.
Hodgkin’s lymphoma and five patients with
non-Hodgkin’s lymphoma. Accrual to the protocol for early recurrent breast cancer began in October. To date one
patient has been enrolled.
Some patients undergoing ABMR therapy at St. Luke’s will be eligible
to participate in a SandozlSchering study of GM-CSF versus placebo
following autologous bone marrow reconstitution for lymphoma. It
is possible that GM-CSF (granulocyte-macrophage colony stimulating
factor) may shorten the period of neutropenia following ABMR and
might lessen the morbidity associated with this therapy by decreasing
the number of days at risk for infection.
For more information about the ABMR Program please contact Dr.
Robert Taylor (414) 672-1982, ABMR Program Director, or Kathy
Oldham, R.N. (414) 649-6540, ABMR Program Coordinator.
Kathy Oldham, RN.
ABMR Program
Robert Taylor, M.D.
Oncology
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Autologous Bone Marrow
Transplantation I GM-CSF

Autologous Bone Marrow Transplant is
an alternative to patients who have
failed conventional therapy.

New Linear Accelerator In
Radiation OrKology

The third linear accelerator for St. Luke’s
Medical Center was installed and provides
our Radiation Oncology Department with a
‘
V
4r r variety of treatment options. This Varian
2100C accelerator delivers 6 MeV and 8
MeV photon energies for treating both
4_
superficial and deep tumors, and a selection
of five electron energies for treating lesions
close to the skin’s surface. This unit provides
for unique clinical requirements, allowing
Phitomena Whitton, RS, kIT independent collimator motion, high dose
rate electron beam therapy, and an extended
travel range of the patient support system.
The major advantage over our current linear accelerators is the
increased computerization of the 2100C. In the future, this ability
will offer the possibility for computerized control of complex
radiation treatments, an approach called dynamic therapy. In this
approach, the size of the treatment field, angle of the treatment
beam, and position of the patient support system are controlled
by a computer linked to the linear accelerator.
More conventional computerization is provided by the radiotherapy
management system which will be utilized for data entry, as well
as for recording and verifying patient treatment. This system will
provide centralization of all patient treatment data, which will
increase the accuracy and reliability of treatment delivery.
We look forward to continued growth and expansion of services
in the Radiation Oncology Department as part of the overall
cancer program at St. Luke’s Medical Center.
Philomena Whitton, B. S. , R.T.T.
Radiation Oncology
•b

•

,
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To provide a variety of treatment
options, a third linear accelerator was
installed at St. Luke’s Medical Center.
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Dry mouth or xerostomia is a very common
condition. Although it is not life threatening, it
produces numerous symptoms and a diminished
quality of life. Before the development of the
Salitron System, there was no effective
treatment.
Approximately 4 million people in the United
States suffer from xerostomia associated with
Sjogren’s Syndrome or other autoimmune
conditions. An equal number of patients will
Jaflt(’s BrZIL-kntan, iVl. l).
develop a dry mouth from one of the other
causes, such as head and neck irradiation or
use of certain medications.
Patients who suffer from xerostomia have a variety of problems,
including difficulty swallowing, difficulty talking, altered taste,
secondary dental caries or loss of teeth, burning of the tongue or
throat, or poor sleeping. These patients require frequent sips of
water to have some temporary relief. Because there is no effective
treatment, the patients often withdraw from an active life to one
of seclusion and misery.
Earlier this year the Radiation Oncology Section, St. Luke’s
Medical Center, was granted exclusive use of the Salitron by the
developer, Biosonics Inc., for southeastern Wisconsin. This is a
device that produces a low voltage, pulsed electrical stimulus.
When regularly applied to the tongue and palate, like a lollipop
in the mouth, it can stimulate the salivary glands to increase
saliva. Experience indicates about 75% of Sjogren’s patients
experience significant relief of dry mouth and secondary
problems. The FDA has approved the use of the Salitron System
for xerostomia secondary to Sjogrens Syndrome. This is a medical
breakthrough for both it’s effectiveness in reducing dry mouth and
because there are no reported side effects.
The Salitron is not yet approved for treatment of xerostomia from
non-Sjogren’s causes, but these patients can be treated on a multiinstitutional protocol approved by St. Luke’s Medical Center’s
Institutional Review Board.
J ames Bruckman, M.D.
Radiation Oncology

i
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St. Luke’s
Dry Mouth Center

1
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St. Luke’s Medical Center now uses the
Salitron for the relief of symptoms of
xerostomia.
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Care

and

Thatment of

Gynecologic Cancer

Introduction
Gynecological Sites =
Incidence of Cancer at St. Luke’s
Number of patients
1989

1984

1979

Corpus Uteri
42

14

26

11

15

6

14

0

2

5

0

0

1

Cervix Uteri
22
Ovary
10
Vulva

3
Uterus
2
Vagina
2

Fallopian tube and broad ligament
1

1

0

Labium majus and minus
1
*

0

Not specified as corpus or cervix

0

The role of the obstetrician-gynecologist is
traditionally perceived as a physician who
provides primary and specialized care for
women in the reproductive period of their
lives especially in regards to childbearing,
contraception and gynecological disorders.
However, a very important facet of our role is
the surveillance for breast and gynecological
cancers. In both pre-menopausal and post;)
menopausal women, the gynecological exam
which includes breast and pelvic exams and
Carmela A. Bari M.D.
pap smear is a crucial and essential screen for
breast, cervical, uterine and ovarian cancers.
According to the National Cancer Institute’s data, in 1990 an
estimated 29% of all female cancers are breast cancers, 9% are
uterine and cervical cancers and 4% are ovarian cancers. These
statistics do not include pre-cancerous conditions known as
carcinoma-in-situ. For example, 50,000 cases of carcinoma-in-situ
of the cervix are diagnosed annually. In 1990 it is estimated that
there will be 150,000 new cases of breast cancer, 13 ,500 cases of
cervical cancer, 33,000 cases of uterine cancer and 20,500 cases
of ovarian cancer.
Physicians are employing both standard screening and new
diagnostic and therapeutic methods to detect and treat these
cancers which will be discussed in the following articles of this
annual report. Most importantly, the lay public needs to be aware
of the importance of the basic gynecological exam and its role in
detecting cancer in women. Women may neglect to have exams
on a regular basis if they are not motivated by reasons such as
pregnancy, contraception or hormone replacement in the
menopause. Together with our patients as partners in good health
care, we envision an important need for education, surveillance
and treatment of breast and genital tract cancers. By working
together, the medical and public community can favorably impact
upon the health of women through early detection and thereby
improved outcomes.
Carmela A. Barr, M.D.
Gynecology, Chief
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Carcinoma of the Cervix
The reduction of the incidence of cervical
cancer is directly related to papanicolaou
smear testing. It has decreased from
25/100,000 women in 1945 to 10/100,000 in
1985. It could be reduced further with
increased compliance and wider use of annual
pelvic exams and pap smears.
It has been stressed that annual pap smear
testing can reduce a womans chance of dying
Julie O’Reilly, M.D.
from cervical cancer from 4/1,000 to
5/10,000; a 90% difference. The purpose of
screening should be to identify preinvasive disease early when the
treatment modality is less invasive. Sexually active women of all
ages are susceptible to preinvasive disease.
The development of cervical cancer is related to the multiple
“insults” the cervix sustains. It is not seen in the celibate population.
There is a correlation between cervical cancer and coitus at an
early age, multiple sexual partners, smoking, and the Human
Papilloma Virus (HPV).
The association of HPV-16 and HPV-1$ and cervical cancer is
very strong. It is likely that the virus requires co-factors to induce
cancer. Prevention of HPV infections may reduce the incidence of
cervical cancer. Early lesions are often identified by the Pap smear.

Prevention of
Pelvic Cancer

Endometrial Cancer
Endometrial cancer is the most common invasive neoplasm of the
female genital tract. There are 40,000 new cases per year.
Characteristics associated with increased incidence of the disease
are:
Obesity Enhanced conversion of androstenedione to estrogen
in fat cells results in an unopposed estrogen environment
Anovulatory Cycle Oligoamenorrhea
Unopposed Estrogen Replacement Therapy
-

-

Family History of Disease
Low Parity
Prevention of obesity and unopposed estrogen stimulation is
important in the prevention of Adenomatous Hyperplasia and
Endometrial Cancer.
The identification of young women with oligoamenorrhea and
correction of this with progesterone may decrease the incidence of
cancer.

7

Cancer prevention education is important
for women of all ages.

Prevention of
Pelvic Cancer
(continued)

Cervical
The risk ofSquamous
.
.
timesfor
3.9
increased
Cancer was
.
.
women with Papanicolaou smears at
three year intervals compared with
women with annual screening.
C’

•

.

“

*

Kirk Shy et. aL Pap Smear Screening Intert’al
Obstetrics & Gynecology, Vol. 74, No. 6, 12/89
,

Comment On The Rates
In Corpus Uteri

Ovarian Cancer
The prevention of ovarian cancer is not within our grasp. There
are 12,000 deaths per year from this disease. It appears that the
risk of ovarian cancer increased in industrialized nations, among
women of low parity, with a strong family history of ovarian,
endometrial or breast cancer.
It has been documented that the use of the oral contraceptive pill
may reauce tue incruence ot ovarian cancer. I nis may e clue to
tne aecrease or tne trauma or ovulation wmcn couia De a
co-factor for the disease process.
Women with known risk factors may benefit from ultrasound
screening, CA 125 levels, as well as annual pelvic exams.
Julie O’Reilly, M.D.
Gynecology
.
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The St. Luke’s survival rates are probably somewhat lower than
the national average since many patients with early disease are
treated with surgery alone. During the period from 1979 to 1984,
the amount of gynecological surgery done primarily at St. Luke’s
was less than what it is at this time. Consequently, many of the
patients who were seen in our institution were those who had
more advanced disease requiring combined treatment or medically
inoperable or not eligible for optimal treatment. This would
adversely affect the survival rates with a lower overall survival,
although when reviewed stage for stage, the result would be
essentially similar.
Marcia J.S. Richards, M.D.
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1989 Cancer of Corpus Uteri
42 Patients

—

1989 Cancer of Corpus Uteri
42 Patients

30-39 24%
40-49 4.8%

>

8Q 4.8%

60-69 42,8%
Local 73.8%

Regional Nodes 2,4%

50-59 16.7%

Unkown 7.1%

Distant 7.1%
Regiona’ Direct Ext. 95%
70-79 28.6%

Age of patients at diagnosis

Stage of patients at diagnosis

Corpus Uteri All Stages
Survival Rates 5yrs
-

Corpus Uteri First Course of Treatment
National

Surgery only

1979-1984*
Radiation only
Surgery & Radiation
Surgery

a

Chemo

SLMC
1979-1 984

Surg/Radiatlon/Chemo

58%
No Treatment
0

10

—

20
30
40
50
Percentage of Patients

1989 42 pta

60

70

0%

20%

40%
60%
Percent

80%

100%

*
From Cancer Facts & Figures, 1989
American Cancer Society
Based on cases diagnosed in 1979-1984

1984 14 pta

[.:.7979 26 pta
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Early Detection Of
Gynecologic Cancer

Essential cancer screens for women are
breast and pelvic exams and pap smear.
Carmela Barr, M.D., gynecologist,
examines with a colposcope.

Screening tests ideally are easy to perform,
inexpensive, painfree, and reliable. Presently,
none of these apply 100% to endometrial
cancer (cancer of the uterine lining) or ovarian
cancer. Therefore, it is recommended that
gynecologists select patients at higher risk for
developing these cancers and perform screening
tests on this higher-risk group.
Endometrial cancer, like most cancers, can be
treated very successfully if it is found early.
Craft. M.D.
Thirty thousand American women per year
will develop endometrial cancer. Three fourths
of these patients will present as Stage I (early) disease. Unfortunately,
3,000 women per year will die from endometrial cancer. This
cancer affects menopausal women predominantly. The most
common sign of its presence is bleeding. Therefore, every
menopausal woman who bleeds must be evaluated by her doctor as
soon as possible. Her physician will probably perform a
hysteroscopy (looking inside the uterus through the cervical canal
with a narrow tube) and/or a D & C. These are minor outpatient
operations. But, what of screening? A targeted high-risk patient
population to evaluate before the sign of potential cancer develops
would be a woman who is menopausal, obese; perhaps diabetic or
hypertensive, and a woman who had a prior history of menstrual
irregularities, specifically infrequent and irregular menstruation. The
best screening test would be an office endometrial biopsy or
aspiration with a suction instrument. This test is mildly uncom
fortable; it is moderately expensive; it does take training to perform,
and it is reasonably reliable. As you can see, it is not an ideal
screening test, but in a selected population it can be very valuable.
Ovarian cancer screening is an even more difficult issue. Twenty-one
thousand women in America will develop ovarian cancer per year.
Twelve thousand women will die. Unfortunately, three-fourths of
the new cases of ovarian cancer per year present at an advanced
class (Stage III). Detailed ultrasound through the vagina of the
ovaries and a blood test named CA-125 have been recommended
as screening tests. The ultrasound is quite expensive to perform,
and the blood test is very imprecise. It has been suggested that these
two screening tests be performed on women at high risk for
developing ovarian cancer. This sub-group of women have a history
of two first degree relatives with ovarian cancer (mother, sister). It
has been estimated that women with this history have as much as
a 50% chance of developing the disease, whereas women without
a family history have only a 1 in 70 risk. Women with this history
as well should have pelvic examinations every four to six months
from age 20 on. Some physicians even recommend prophylactically
removing the ovaries at age 35 to 40 when childbearing has been
completed.
Samuel Craft, M.D.
Gynecology
10

1989 Cancer of Ovary
10 Patients

1989 Cancer of Ovary
10 Patients

Distant 40%

40-49 10%
70-79 30%

30-39 10%

Regional Ext,& Nodes 10%

Local 20%

Regional Nodes 10%

o0-5g 20%

60-69 20%

Regional Direct Ext. 20%

Age of patients at diagnosis

Stage of patients at diagnosis

Ovary All Stages
Survival Rates 5yrs
-

Ovary First Course of Treatment
Surgery only

1:1

National
1979-1984*

Radiation only
Chemotherapy only
Surgery

a Radiation

Surgery

a

Chemo

SLMC
1979-1984

Surg/Rauiatjon/chemo
No Treatment
0

L

20

—

40
60
Percentage of Patients

1989 10 pts

1984

80

100

I
0%

10%

20%

30%

40%

50%

Percent

6 pts

From Cancer Facts & Figures, 1989
American Cancer Society
Based on cases diagnosed in 1979-1984
*

1979 74 pts
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MRI For Gynecologic And
Other Pelvic Tumors

Magnetic Resonance Imaging improves
diagnosis and treatment planning in
pelvic tumors.

Magnetic Resonance Imaging (MRI) of the
pelvic region offers several distinct advantages
for the diagnosis and staging of pelvic malig
nancies. The examination is safe with no
ionizing radiation and usually no need for
intravenous contrast media. The imaging
technique allows direct images in multiple
scanning planes for improved diagnosis and
treatment planning. Magnetic Resonance
images clearly provide excellent soft tissue
Michael Kehoe, M.D.
contrast, allowing the ability to separate
tumor from normal issues more clearly than
other imaging modalities. Extension to adjacent structures and
previously unvisualized lymph drainage area is allowed by this
unique imaging modality.
At this time, the MM role in oncology is primarily that of staging
the extent of tumor size and spread for the proper selection and
application of treatment, whether surgery, radio-, chemo-, or
immunotherapy, and susequent monitoring of tumor response.
The non-invasive nature of the examination and lack of ionizing
radiation allow safe follow-up examination at no additional risk
or discomfort to the patient. There are selected roles for detection
of occult lesions not visualized by other techniques.
Unfortunately, screening applications are limited by the current
relatively high cost. As clinical experience increases and further
technologic developments unfold, the combined uses of Magnetic
Resonance Imaging with other cross-sectional imaging modalities
will allow extremely accurate three-dimensional radiotherapy treatment planning and delineate the role of this exciting new modality
in screening and early detection protocols for both male and female
pelvic malignancy.
Michael Kehoe, M.D.
Radiology
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Surgery has long been a mainstay in the management of women
with various reproductive tract cancers. Historically, many of the
techniques that are done today were handed down from surgeons
of the early part of the 20th century. There have been modifica
lions made in some of the techniques, but many still remain quite
similar to our predecessors.
Specifically in treating women with cancers of the cervix, lesions
that are localized to the cervix alone may be treated with radical
hysterectomy and bilateral pelvic lymphadenectomy. In this
procedure some of the normal as well as all of the abnormal tissue
needs to be taken. Because of this there is an increased risk of
having injury to either the urinary or gastrointestional systems.
Our techniques, however, have come a long way in preventing
much of the morbidity from this surgery. A benefit for a young
woman with a cervical cancer who would choose to have a surgical
approach for her cancer of the cervix would be the preservation
of the ovaries. Certainly, since for early stage lesions the cure rate
is the same for surgery or radiation therapy, arguments can be
made for either, and often it comes down to physician and patient
preference.
In treating endometrial cancer, historically a hysterectomy, bilateral
salpingo-oophorectomy has been the mainstay of treatment. Since
most of these cancers are early staged, i.e. confined to the uterus
at the time of their presentations, the cure rates are extremely
good. Oftentimes no adjuvant therapy is needed for them.
However, our studies have now indicated that there are certain
women at increased risk for recurrent disease and that after the
surgery is completed, radiation therapy may be of some benefit in
decreasing the likelihood of recurrent disease for them.
Finally, in ovarian cancer the concept of hysterectomy, bilateral
oophorectomy, and tumor debulking has long been written in the
GYN literature. Within the past fifteen years great strides have
been taken to better define how aggressive a surgeon is at the
time he is confronted with an ovarian malignancy. Literature now
shows us that if we are able to decrease the tumor burden down
to a size of less than 2 cm for any individual tumor nodule, then
the chances that chemotherapy will be effective is much better.
Oftentimes, however, a more palliative surgery needs to be undertaken to establish first a diagnosis of an ovarian cancer and then
second to try to make the patient more comfortable. Newer
techniques, for example laparoscopic surgery and laser surgery in
GYN oncology, are just now starting to be examined in clinical
trials. Their benefit still awaits further time and operator
experience.
Elmer G. Lehman, M.D.
Gynecology
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Gynecologic
Oncology Surgery

Surgery plays an important part in the
treatment of gynecological cancers.
Elmer Lehman, M.D., a gynecologic
oncologist, uses a laparoscope in surgery.

Radiation Treatment In
Gynecologic Cancer

Radioactive implants are used in the
treatment of cervical and endometrial
carcinoma.

Gynecologic or female tract cancers, taken as a
group, are annually responsible for an estimated
25 ,000 cancer deaths in the United States.
Although early detection of cervical cancer by
pap smear has reduced the incidence of invasive
cervical carcinoma by 50% in the last several
decades, GYN cancer ranks 4th among cancer
deaths in women today. Since most women with
gynecologic cancer die of disease in the abdomen
and pelvis, local and regional control of cancer is
/7
a paramount issue in this disease. This is the
1K/i1liani I. Rio,
reason why radiation therapy has and currently
still assumes an important role in the treatment of GYN cancer.
Radiotherapy of gynecologic cancer can be utilized alone or in
combination with surgery; and radiation therapy can be delivered by
linear accelerators (teletherapy or external beam) and/or radioactive
material (implants or brachytherapy). If the therapy is the only
modality, external beam plus implants are needed to achieve a high
enough local dose to achieve a cure. The advantage of using an
implant is that one can deliver a high dose locally to the tumor while
relatively sparing the surrounding normal tissue. Combined with
surgery, the total dose required is reduced. Hence external beam or
implant alone may be sufficient.
Radiotherapy is most commonly used in cervical and endometrial
carcinoma. In the cervix, radiation therapy is the treatment of choice
in tumors that have invaded the parametrial (Stage Il-B or higher) and
is an option of treatment with early stage tumors as well. A course
of external beam radiation therapy followed by two implants is usually
used. In endometrial carcinoma, radiotherapy is often used after a
hysterectomy for patients at high risk for local recurrence; usually
external beam is delivered followed by an intracavitary insertion with
ovoids to the vaginal cuff. Vaginal carcinoma is often treated by
radiotherapy alone due to its location and external beam plus implants
are again needed. In ovarian carcinoma, since the abdomen is the
primary mode of spread, whole abdominal radiation therapy is an
option after primary surgery debulking and also after a positive second
look surgery, after chemotherapy. Excision of local vulva carcinoma
followed by radiotherapy is an alternative to a radical vulvectomy in
lymph node dissection.
Radiotherapy has been used for gynecologic cancer for over seven
decades. Progressive technical advances and clinical studies have allowed
us to maximize therapeutic potential of radiation therapy while
minimizing its late effects; customized blocking, changing patient posi
tion to reduce small bowel volume, and decreasing brachytherapy dose
rates to the incidence of bladder and rectal complication rates. Future,
chemotherapy and hyperthermia combined with radiation therapy will
be the subject of more intensive studies. Much has and more will be
learned to continue the therapeutic potential of this modality.
William J. Pao, M.D.
Radiation Oncology
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1989 Cancer of Cervix Uteri
22 Patients

1989 Cancer of Cervix Uteri
22 Patients

20-29 4.5%
4549 4,5%

.

30-39 36.3%

80-89 4,5%
50—59 9%

Regional Direct Ext. 16.2%
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Systemic Treatment Of
Gynecologic Malignancy

Endometrial cancer represents 13 % of all
malignancies in women; ovarian tumors, 6%;
uterine cervix tumors 6% ; and other
reproductive tract tumors 2-3% For those
patients who present with advanced or recurrent gynecologic cancer, systemic treatment
with hormones and chemotherapy has a
significant role.
For epithelial carcinomas of the ovary, a large
number of cytotoxic agents have been shown
Gerald I. Kallas, M.D.
be active. Dramatic improvement in
frequency of response has been noted with
the use of cisplatin-based combination chemotherapy as compared
to single alkylating agents. Studies with the new platinum
analogue carboplatin have shown equal efficacy in response rates
with significantly less toxicity. More recent studies have evaluated
alternative pathways to employ the platinum compounds with
higher dose schedules or intraperitoneal administration. None has
been shown to be superior to a combination of a platinum
compound plus an alkylating agent with or without doxorubicin.
The role of hormone therapy in ovarian carcinoma is limited and
responses have been of short duration.
In endometrial carcinoma, progestins and doxorubicin are the
most active agents. Tamoxifen, cisplatin, carboplatin, 5-FU, and
hexamethylmelamine appear to have moderate activity. No
combination to date has been shown to be superior to single agents.
For squamous cell carcinoma of the cervix, cisplatin has been
shown to be the most active agent. Its use is frequently limited in
these patients because of associated renal compromise due to
obstructive uropathy. While a number of other agents have shown
moderate activity, no combination has been shown to be superior
to single agent cisplatin. Hormonal therapy has not shown any
activity in cervical cancer.
There are many new approaches currently being investigated
including high dose chemotherapy with autologous bone marrow
transportation for ovarian carcinoma, monoclonal antibodies, and
the different types of biologic response modifiers such as alpha
and gamma interferon, interleukin II, and activated natural “killer”
lymphocytes. These therapies are still considered investigative.
Gerald J. Kallas, M.D.
Oncology
.

16

The goal of inpatient gynecological nursing
care is to promote the maximal health for the
woman and her family. On 5GHJK the focus
of nursing is on integrating the psychological,
medical and surgical principles into the plan of
care. The nursing process provides a dynamic
framework for the planning, implementing and
evaluation of the care of the patient undergoing
surgical intervention for gynecological cancer.
The nursing care is based on an assessment of t
Kerry Twite, RN.
the woman’s health and may include:
1. Assisting women to reach postoperative milestones.
2. Providing anticipatory guidance and emotional support related
to alterations in body image, self-concept, reproductive status
and sexual functioning.
3 Providing health education on changes in the hormonal
environment: relief of menopausal symptoms, preservation of
bone mass, prevention of cardiovascular disease, improvement
in one’s sense of well-being, and prevention of sexual and
urinary problems.
4. Providing adequate pain management. The nursing staff
works closely with the physician, family and other members
of the health care team to insure comprehensive, coordinated
health care.
Patients who require inpatient nursing care for chemotherapy and
for brachytherapy are generally hospitalized on the inpatient
oncology unit. The nursing care of those women who receive
chemotherapy is focused on monitoring for side effects and
managing the side effects identified. Patients are provided with
numerous resources to enable the woman to become knowledgeable
about her treatment and how best she can help herself manage
her side effects.
Care of the gynecological patient requiring a radiation implant
has two main concerns: safety for the patient and pain management. The care of the woman with a gynecological malignancy
addresses the multiple concerns of these patients.
Kerry Twite, R.N.
Oncology Nursing

Gynecologic
Oncology Nursing

.
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Nursing goals are to promote maximal

health for women and their families.
Lynette Gagnon, Womens Health Program
Coordinator, counsels a family.

Oncology Social Work

Cancer is a family experience. It almost
always affects emotional, material, and social
resources, as well as the physiological. The
Oncology and Womens Health Center Social
Workers are aware of this. They specialize in
assisting the woman who has cancer, and her
family, cope with the multitude of problems
that can accompany diagnosis and treatment.
They work with patients in the context of
the woman’s many roles in the family:
spouse, caregiver of both children and elders
Grace McCutcheon
( often simultaneously), and in the work
place, as well as an individual and a patient.
The social worker will help the woman from outpatient care and
decision-making through hospitalization, discharge planning and
follow-up, with differential referral to appropriate resources in the
community as well as the health care system.
Continuity of care and self-determination for the patient are emphasized throughout this process.
Grace McCutcheon
Social Services
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Cancer Of The Ovary
Long And Short Term Study
American College Of Surgeons
-

h
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St. Luke’s participated in this national study in 1989. One of the
purposes of this study is to document changes in diagnostic and clinical
management of ovarian cancer in the United States. We compared data
from
1988, to five years ago, 1983. Successive cases were chosen
starting with January of each year, 7 patients in 1983, 10 patients in
1988. All patients were diagnosed at St. Luke’s and for the most part
received their first course of therapy here. All cases were required to
have a positive microscopic histology. Following are some of the more
interesting comparisons.
What are the ages of the patients?
40-49
50-59
60-69
70-79
80-89
1983
1
2
2
1
1988
2
0
3
4
1
Number of Patients

Patient Characteristics:
Family history of cancer
Patient history of cancer
Normal term deliveries
Abortions
Cystic, serous, mucinous histologies
Adenocarcinomas
Ascites present at diagnosis
Symptoms at diagnosis
Abdominal swelling/bloating
Abdominal pain
Weight gain
Constipation
Self-palpation of abdominal mass
Diarrhea
Abnormal vaginal bleeding
Tests done at diagnosis
Abdominal ultrasound
Barium enema
CT scan of abdomen
CT scan of pelvis
Upper gastrointestinal series
Proctoscopy
Intravenous pyelogram
Tumor markers done
AFP
CA12S
CEA
HCG
None
Recurrence
Never disease free
Kathy Bielinski
Cancer Registry
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2
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4
2
4
3
3
2
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6
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5
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2
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1
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2
3
1
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Long and Short Term Study
(cotted)

Stage at Diagnosis
1110 43%

1110 50%
lB 14%

A 29%

lv 14%

1983
lB 10%

10%

1988
STAGE GROUPINGS
Stage IA Ti a
Stage lB Tib
Stage IC Ti c
Stage hA T2a
Stage lIE T2b
Stage IC T2c
Stage lilA T3a
Stage IIIB T3b
Stage IIIC T3c
AnyT
Stage IV Any T

NO
NO
NO
NO
NO
NO
NO
NO
NO
Ni
Any N

MO
MO
MO
MO
MO
MO
MO
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MO
MO
Mi
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Long and Short Term Study
100%

(continued)

Survival Curve
•
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80%
70%

70%
Percentage
of
Patients

20%

120%

10%

-

14%

0%

74%
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0
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p

14%
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2
3
4
Years patients survived
—.—

1983

---

5

6

1988

Note: The survival rate of our patients has improved even though we are treating more patients with advanced stage
of disease.

First Course of Treatment

Biopsy only

Surgery only

Surgery & Chemo

0

2

4
6
Number of Patients

[

1983
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1988

8
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Cancer Scitening Pmgmms

Head And Neck
Screening Program

Screening programs can be effective in
preventing cancer. James R. Barton,
M D. otolaryngologist, participated in
the Head & Neck Cancer Screening
Program.
.

,

The total number of newly diagnosed cases
of head and neck cancer in the United States
is estimated at around 67,000. This
represents about 5% of all new cancer cases
in the United States.
Head and neck cancers seem to be associated
with some known high-risk factors, smoking,
alcohol use and use of smokeless tobacco. A
screening program whose target population
would encompass the high-risk groups might
Susan i\ticLlV, K. \.
be effective in preventing head and neck cancer.
In January of 1990 a Head and Neck Cancer
Screening Program was implemented at
St. Luke’s Medical Center. Thorough assessment
and careful inspection of the oral and
oropharyngeal were performed. An indirect
laryngeal exam was also conducted during
the screening. Following the screening, Vince
Lombardi Cancer Clinic and Diagnostic and
Treatment Center nurses, along with the clini
cal nurse specialists, conducted counseling
and educational sessions for those screened.
Information about stop smoking classes,
cancer-related information and risk factor identification was made
available.
To date, the program has screened 347 persons. Sixty percent of
those screened had a previous family history of cancer; 25% of
people screened were presently smokers, with an additional 12%
who quit in the past year. Fifteen percent could be considered to
have a moderate intake of alcohol.
Many people were found to have leukoplakia on the vocal cords,
pharynx or oral cavity. All of the people were smokers! A recom
mendation to stop smoking was made along with a six (6) month
follow-up screening. Appropriate referral and follow-up were
recommended.
The Head & Neck Screening program needs to continue. Followup for those people already screened at high risk needs to be
done. A goal of the future is to screen only those people who
have significant risk factors.
This screening program is feasible, as well as useful, to our
community. Through early detection, we hope to see morbidity of
head and neck cancer minimized, survival rates increased and
through prevention, incidence decreased.
Susan Nuccio, R.N., M.S.N.
Clinical Nurse Specialist
J ames R. Barton, M.D.
Otolaryngology
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Prostate Cancer Awareness Week was held
nationally during the week of September 16-21,
1990. The Section of Urology of St. Luke’s
Medical Center participated in the prostate
screening program seeing patients in the
Diagnostic and Treatment Center with the
cooperation of the nursing personnel there.
Not only did the urologists of the section
donate their time the nursing service did likewise. Together we were able to see 234 men
during this period of time. After the men filled
Barry Usow, M.D.
out questionnaires and they were processed by
the Diagnostic and Treatment Center personnel the urologist
examined the patient and did digital rectal examinations.
of the 234 men who participated 52 men were found to have an
abnormal examination which is approximately 22% of those
examined. These men were referred to their private physicians,
local urologists, or given the name of the urologist of our section.
The majority of the men who participated in this screening
program felt that the information they were given for the program
was extremely useful and that they would come back for a
second screening a year from this time.
We are very proud of the participation of the urologic and nursing
staff in making this program successful. We look forward to
continuing this participation in the future.
Barry Usow, M.D.
Urology

Prostate Cancer
Screening Program

Barry Usow, M.D., urologist, prepares
to examine a patient during the prostate
screening program sponsored by
St. Luke’s Medical Center and the
Department of Urology.
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Special Studies

Cancer Detection In The
Emergency Department:
A Failure Of Primary Care

“The growth of Emergency Medicine has been
due in large part as the result of a failure of
primary care,”
Carl Yonkerman, M.D.,
Dean Froedtert Memorial Lutheran Hospital.
An estimated one million patients visit
Emergency Departments each year in the
United States. Acute chest pain of cardiac
origin and acute injuries are the leading
causes for these visits. Patients presenting
Marcia JS. Richards, M.D. with a myriad of complaints which ultimately
result in a diagnosis of a neoplasm account
for a small but significant portion of patients
seen in the Emergency Department. This
study was undertaken to describe the
epidemiology of patients presenting to a
community Emergency Department with
acute problems, resulting in admission to the
hospital and a diagnosis of a cancer made on
discharge from the inpatient setting.
Materials and Methods
Cases were included which:
1. were newly registered in the tumor registry
Alfred Anderson
2. entered the hospital through the Emer
gency Department and thus generated an Emergency
Department record
3 had no known previous cancer or who had been free of
cancer for greater than 5 years or who had a newly diag
nosed primary cancer
Patient records were abstracted, data entered into a computerized
spreadsheet and analyzed.
Results
One hundred and sixty-three patient records were reviewed for
1986 through six months of 1988. One hundred and thirty-one
records met the case definition and were subsequently abstracted.
Seventy-four of the cases were males, the mean age was 65. The
crude rate of cancer patients presenting in the Emergency Department for 1986 was 5$ cases for 29,460 visits. In 1987, the rate
was 54 cases for 31,394 visits. And in 1988, there were 19 cases
for 14,778 visits. Over the study period, there were 2,000 new
cases of cancer which were entered in the tumor registry. The
Emergency Department accounted for 131 of these cases, thus
accounting for an estimated 5%.
.

Emergency rooms sometime serve as
entry points into the health care systems
for patients who have let their cancer
progress into acute symptoms.
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Discussion
Emergency Medicine has evolved over the past 30 years to
become the specialty of breath, acute care and resuscitation. In
addition, the Emergency Department serves as the entry point to
the health care system for individuals with urgent problems, no
insurance or personal physician. The cancer patients in this study
point to the problem of those patients whose neoplasms has
progressed to the point where they have acute symptoms associated
with them. Emergency Departments are not places in the health
care systems set up for screening and early detection of cancer,
yet patients present to Emergency Departments with a host of
difficult and different complaints, some of which may be early
signs of cancer. The authors are not advocating screening
programs in the Emergency Department, but rather strong followup recommendations, as there were probably a number of patients
who may have had early cancer problems, but were not detected
in the Emergency Department. This study may also reflect a
certain patient population which is particularly difficult to reach
by standard educational approaches. They typically state that they
“never go to doctors’ or simply “hate doctors’ or “hate hospitals’
The poor prognosis of these patients as demonstrated in our
results suggests that intensive identification of these patients would
result possibly in early diagnosis of cancer.
Stephen Hargarten, M.D.
Emergency Medicine
Marcia J.S. Richards, M.D.
Radiation Oncology
Alfred Anderson
Data Registry
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Cancer Detection
(continued)

Total charts pulled
Total records used

-

-

163
131

Age Breakdown

Male Female

90+ 1889-1899
80-89 1909-1900
70-79 1919 -1910
60-69 1929-1920
50-59 1939-1930
40-49 1949-1940
30-39 1959-1950
20-29 1969-1960

-

-

-

-

-

-

-

-

8
30
37
34
13
5
3
1

2
14
26
19
7
2
3
1

Total ER 1986 29,460
census
1987 31,394
Jan 1 June 30, 1988

6
16
11
15
6
3
0
0

-

-

-

CA patients from ER

Total Female
Male-

-

57
74

1986
1987
1988

-

-

-

58
54
19

-

14,778

Myelodysplastic
Syndrome (MDS)
Table 1 : FAB Classification of MDS
MDS

Substypes

Blast Celif %)

Additional

Dyspoiesis

Peripheral Bone
Blood
Marrow
MDSI-RA

1

5

MDS II

1

5

RARS

-

+

Ringed
sideroblasts

±

15%
MDS III

-

MDS IV

-

RAEB

5

5-20

CMML

5

5-20

+

+

+

+

Aner rods
+
(regardless of
the blast count

+

P. Monocyte
count

1 x i09/L

[

MDS V

-

RAEBT

5

20-30

Abbreviations:
RA refractory anemia.
.

-

RARS
RAEB

-

-

CMML
RAEBT

RA with ringed sideroblasts.
RA with excess blasts.
-

-

Chronic myelomonocytic leukemia.
RAE B in transformation.

Dyspoiesis:
+ mild,
± mild/none,
+ + moderate/severe.

.

.

The myelodysplastic syndromes (MDS) are a
group of clonal hematopoletic stem cell
disorders characterized by abnormal bone
marrow differentiation and maturation,
leading to peripheral cytopenia and high
probability of eventual leukemic conversion.
History
A few decades ago, it was recognized that
some of the patients with acute non
lymphoblastic leukemia (ANLL), had a
variety of pre-existing blood conditions and
hematologic abnormalities preceding the onset of leukemia by
months or years. These disorders have had various names in the
past, such as refractory anemia, preleukemia, preleukemic anemia,
preleukemic leukemia, refractory normoblastic anemia, sideroblas
tic anemia, smouldering leukemia, hemopoietic dysplasia, dysmye
lopoietic syndrome, oligoblastic leukemia and preleukemia.
Because of the confusion with this nomenclature, in 1982, a
group called the French-American-British (FAB) proposed the term
a myelodysplastic syndrome or (MDS), which has been generally
accepted. The classification is based on the following morphologic
criteria (Table 1); (1) percentage of blast cells in the bone marrow
(BM) and/or peripheral blood (PB); (2) presence of ringed sidero
blasts in the BM; (3) absolute peripheral monocyte count; (4)
presence of Auer rods.
Table 1 gives the current classification of refractory of
myelodysplastic syndrome. ft should be noted that while there is
no doubt that the FAB classification was the first comprehensive
attempt to set diagnostic and prognostic guidelines, there are still
several problems using it.
(1) This is a morphological classification, while clinical and
hematological features do not always correspond to the
morphological definitions.
( 2) Such classifications leads to subjective and not necessarily
reproducible diagnosis, based on the personal skill of the
person reviewing the smears.
(3) The definitions are somewhat arbitrary.
(4) Some people are questioning inclusion of the CMML in this.
( 5) The correlation between the morphology and cytogenetics or
immune markers is limited.
Clinical and Hematological Picture
The typical patient is in his 70’s. Both sexes seems to be equally
affected. Common symptoms are fatigue, weakness, 30% to 80%
related to the anemia, and the other symptoms include weight loss,
anorexia, easy bruisability or bleeding episodes, fever, and recurrent
infections. About 6% to 50% of the patients are asymptomatic and
are diagnosed following abnormal blood counts, performed for
unrelated reasons.
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Physical examination is usually unremarkable, and may reveal pallor
as the most common finding in about 60% petechiae or purpura
in the skin or mucous membranes in about 75% splenomegaly
in about 70% hepatomegaly in about 10% lymphadenopathy or
skin nodules are found very rarely, and mostly in CMML patients.
About quarter of the patients may have no physical finding.
The hallmark of the laboratory picture of MDS is anemia, and it
is not wise to make a diagnosis in patients with a normal
hematocrit. Anemia only is found in about 15% of the cases.
About 50% present with pancytopenia, 20% with anemia and
thrombocytopenia, 5% with anemia and leukopenia and less than
5% with isolated leukocytosis or monocytosis, leukopenia and
thrombocytopenia.
Very rarely patients present with thrombocytosis, especially with a
5 q-syndrome. The lymphoid lineage is often affected with
peripheral lymphopenia and decreased number of T-helper cells.
The anemia is anemia with a reticulocyte count that is low to
normal, usually normochromic, normocytic or macrocytic with a
high MCV. Serum iron is normal to increased, iron binding
capacity is normal to decreased, serum ferritin is high, consistent
with increased iron stores in the marrow, Vitamin B12 and folic
acid metabolism is usually normal. HbF levels are elevated in
80% of the patients. Erythrocytes from MDS patients occasionally
have increased lysus in the sucrose hemolysis test and less frequently
in the acidified serum test or the Ham’s test. Erythrocyte
cholinesterase activity is occasionally low. Changes in the blood
group antigen expression were also described, i.e. an increase in
erythrocyte i antigen and a decrease in Al and H substances.
The abnormal laboratory features in the myelomonocytic series
include low LAP score, myeloperoxidase (MPO) deficiency and
increased monocyte type esterase 20% of these patients have
increased lysozyme (muramidase) activity in the blood or urine
Functional abnormalities of B, I and natural killer (NK) cells
were reported
Coagulation abnormalities may present, particularly with
prolonged bleeding time, despite the platelet count being normal,
due to decreased platelet function.
Cytogenetic abnormalities are detected in about 40% to 90% of
patients, and in almost all patients with secondary to therapyrelated MDS. The chromosomal changes may be single (simple)
or multiple (complex). The common (although not specific)
abnormalities are deletions of all or portions of chromosome 5
(-5, Sq-), and chromosome 7 (-7, 7qj, trisomy 8 (8 +), and deletion
20 (2Oqj.
In summary, of the cytogenetic abnormalities, the presence of an
abnormal karyotyrpe usually indicates poor prognosis compared
with a normal cytogenetic pattern. Multiple chromosomal changes
often seen in secondary MDS patients is considered a poor
prognostic factor.

Myelodysplastic Syndrome
(continued)
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Myelodysplastic Syndrome hematologic
disorder which precedes leukemia.
-

d

Myelodysplastic Syndrome
(cotie)

Table 2: The Prognosis of MDS (2,4,6)
MDS Subtype

Leukemic
Median
Conversion (¾) Survival (Months)

RARS

0-it)

60-71

7-15

60-65

CMML

20-30

8-25

RAEB

32-56

7-21

RAEBT

40-60

5-16

ALl. MDS

22-27

7.5-27

RA

Table
A. Major:

3: Prognostic Factors in MDS
1. FAB Classification
2. Percent of blasts

3. Cytogenetic abnormalities
4. Secondary MDS

;
B.Minor

1 Pancytopenia
2. Trilinear dysplasia
3. Abnormally localized immature
precursors (ALIP)
.

4. Cloning efficiency of GM-CFC
5. Ia (HLA-Dr) and Mo1 (CD115)
expression
6. Weight loss
7. Fever

8. Age (?)

In general, with exceptions (5q syndrome and possibly monosomy
7 and secondary MDS), no specific chromosomal abnormalities
have been associated with specific clinical or morphological subset,
as described by the FAB criteria.
Management of MDS
Once the diagnosis of MDS has been established, the patient
should be evaluated and classified according to favorable or
unfavorable prognosis factors.
If the patient meets criteria for favorable prognosis, i.e. absence of
the major criteria of unfavorable prognosis, then serial examinations
with bone marrow is recommended. If the clinical course is stable,
supportive care including red cell and platelet transfusions with
antibiotic, when indicated, should be sufficient. A therapeutic trial
with Pyridoxine is justified in patients with RARS. Folic acid and
Vitamin B12 should be given only to patients with these deficiencies.
An unfavorable prognosis patient who is under 50 years of age,
and has a compatible donor, should be offered allogenic bone
marrow transplantation. Young patients with unfavorable disease
who have no donor may benefit from aggressive anti-leukemic
chemotherapy. Older patients with unfavorable prognosis may be
offered low dose ARA-C, aggressive chemotherapy, or 13-cisretinoic
acid. Danazol may be selected for thrombocytopenic patients with
high platelet associated IgG, and corticosteroids may be
administered to those in whom bone marrow cells show invitro
steroid sensitivity.
At the present moment, GM-CSF and G-CSF represent interesting
possibilities for an MDS subgroup who have no alternative, or as
an adjuvant therapy with BMT or chemotherapy. Patients who
have no preferred regimen or who have failed other treatment
should be offered investigational protocols, i.e. with CSFs,
differentiating agents or low dose antienoplastic agents (i.e.
5-azacytidine, and Idarubricin).
Ajit Divgi, M.D.
Oncology, Hematology
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Cancer Regtry Report

The St. Luke’s Medical Center Cancer Registry has been in
existence since 1960, with over 15,000 total patients. In 1989,
1,216 new patients were accessioned into the registry: 1,069
analytic, 147 non-analytic.
With thoughts to the expanding uses of the registry in the future,
computer software was updated during 1989. The CanSur 3.0
version released by the American College of Surgeons was
implemented with the assistance of the Aurora Health Care
Systems Development Department. CanSur features an expanded
data set that exceeds the requirements of the Commission on
Cancer. Additional fields are included for gathering special infor
mation. Changes in cancer case finding and follow-up insure that
the maximum number of patients are accessioned into the registry,
and the lowest possible lost to follow-up rate can be achieved.
The 1989 lost to follow-up/not current rate was only 2% Also
improved were statistical reports which now analyze data in
addition to listing data, including survival analysis. Questions or
requests for information may be directed to 649-6720.
Kathy Bielinski
Cancer Registrar
.

1979
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1989 ALL SiTES DISTRIBUTED BY STAGE
Loca( 52.3%

‘ \

\

Distant 20.1%

Local 42.8%

ry

V
iY

In Situ 31%

Distant 197%

‘

Unkown 5.1%

I Situ 34%
Unkown 4,7%

Regional Direct Ext. 8.7%
RegIona’ Direct Ext. 123%

Regional-Lymph Nodes 9 5%

In 1979, 397 patients were male, 51.8%
369 patients were female, 48.2%

Regional 77%
Both Direct 4 Nodes
Regional-Lymph Nodes 9.4%

In 1989, 585 patients were male, 48.1%
631 patients were female, 51.9%

Note: In site and local stages make up a large percentage of the patients diagnosed each year. Early etection of cancer
contibutes significantly to long term survival.
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Cancer Registry Report
(cottued)
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St. Luke’s
Medical Center
Cancer Research
CALGB #8361: Immunological Diagnostic Studies in Acute Myelogenous Leukemia
CALGB #8393 : National Intergroup Protocol Intermediate Thickness
Melanomas 1.0 to 4.0 mm
Photoradiation Therapy for the Treatment of Malignant Tumors
CALGB #8364: Immunological Diagnostic Studies In Adult ALL
CALGB #8461: Cytogenic Studies in Acute Leukemia
CALGB #8582: A Comparison of Pentostatin and Alpha Interferon in
Splenectomized Patients with Active Hairy Cell Leukemia.
CALGB #8515: Pentostatin in Patients with Acute Hairy Cell Leukemia
Previously treated with Alpha Interferon: A Phase II Study.
CALGB #8534: Combination Chemotherapy with Intensive ACE/PCE &
Radiation Therapy to the Primary Tumor and Prophylactic Whole-Brain Radiation
Therapy with or without Warfarin in Limited Small Cell Ca of the Lung: Phase III
CALGB #8634: Neoadjuvant Chemotherapy, Radio Therapy, and Surgery for
Resectable Stage III Non-Small Cell Carcinoma of the Lung (Limited Access Pilot
Study)
CALGB #8662: Monitoring Circulating Breast Cancer Associated Antigens
with the 15-3 Radioimmunoassay in Metastatic Breast Cancer
A Trial of Surgery Intra-operative Electron Beam and Post-operative
Radiation Therapy in Limited Unresectable or Marginally Resectable Malignancies
CALGB #8691: Cyclophosphamide vs Cyclophasphamide +
Alpha 2 Interferon in the Treatment of Follicular Low Grade Lymphomas: Phase III
CALGB #8362: Pharmacokinetics of ARA-C in Patients with NLL: A Dose
Response Study
CALGB #8642: A Master Protocol to Study Single Agent Induction
Chemotherapy for Stage IV Breast Carcinoma Phase III
CALGB #8751: Etoposide, Vinblastine, Doxorubicin (EVA) as the Primary
Treatment of Advanced Hodgkins Disease in Relapse from MOPP or MOPP Vanants: Phase II
CALGB #8692: Intergroup Phase III Randomized Study of Doconubicin and
Dacarbazine with or without Ifosfamide and MESNA in Advanced Soft Tissue and
bone Sarcoma
CALGB #8763: Immunoglobulin and T-Cell Receptor Gene Rearrangement
Studies in Adult ALL
CALGB #8762: Molecular Subtypes in Philadelphia Chromosome Positive
Acute Lymphoblastic Leukemia
CALGB #8761: Prognostic Implications of the Philadelphia Chromosome
Translocation in Chronic Myelogenous Leukemia
CALGB #8711: Idambicin, A New Analog of Daunorubicin in Acute
Lymphoblastic Leukemia (ALL) at First Relapse on Following Failure of First Line
Therapy A Phase II Study
Treatment of Malignant Gliomas with External Radiation Therapy,
Chemotherapy, Resection, & Computer Assisted Steneotaxic Radioactive Implants
CALGB #8765: Analysis of Proto-Oncogene Expression in Acute
Non-Lymphocytic Leukemia
A Randomized Phase III Comparative Study of the Safety & Efficacy of
Photodynamic Therapy (PDT) Utilizing PHOTOFRIN II vs. Thermal Ablation
Therapy using the Nd: YAG Laser for Obstructing or Partially Obstructing
Bnonchogenic Carcinoma (Protocol D73 P17)
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St. Luke’s Medical Center Cancer Research (continued)
A Randomized Phase III Comparative Study of the Safety & Efficacy of Radiation
Therapy + Photodynamic Therapy (PDT) Utilizing PHOTOFRIN II vs. Radiation
Therapy for obstructing or partially obstructing Bronchogenic Ca (Protocol D7 P18)
A Randomized Phase II Comparative Study of the Safety & Efficacy of
Photodynamic Therapy (PDT) utilizing PHOTOFRIN II vs. Thermal Ablation
Therapy using the Nd: YAG Laser for Partially Obstructing Esophageal Carcinoma
(Protocol P73 P19)
A Randomized Phase II Comparatice Study of the Safety & Efficacy of
Photodynamic Therapy (PDT) utilizing PHOTOFRIN II vs. Thermal Ablation
Therapy using the Nd: YAG Laser for Partially Obstructing Esophageal Carcinoma
(Protocol P73 P19)
A Phase III Study of the Safety & Efficacy of Photodynamic Therapy (PDT)
Photodynamic Therapy (PDT) Utilizing PHOTOFRIN II in Patients with
Completely Obstructing Esophageal Carcinoma (Protocol P73 P 19)
CALGB #8891: Trial of Cystectomy Alone vs. Neo-adjuvant M-VAC +
CYSTECTOMY in Patients with locally Advanced Bladder Cancer
CALGB #8896: A Prospectively Randomized Trial of Low Dose Leucovorin
+ 5FU High Dose Leucovorin + 5FU or Observation Following Curative Resection
in Selected Patients with Duke’s B OR C Colon Ca
CALGB #8862: Population Pharmacodynamic Study of Amonafide
CALGB #8811: Phase II Trial of a 5-Drug Induction Regimen with Intensive
Consolidation in Adult Acute Lymphoblastic Leukemia
CALGB #8861: Monitoring CA 15-3 Antigen in Patients during & after Adjuvant
Therapy for Stage II, Node Positve Ca of the Breast
CALGB #8869: Flow Cytometry Studies in Stage II Node Positive Breast Cancer
MILWAUKEE COMMUNITY ONCOLOGY PROGRAM (MCCOP)
NSABP-20: A Clinical Trial to Determine the Worth of Chemotherapy and
Tamoxifen over Tamoxifen alone in the Management of Patients with Primary
Invasive Breast Ca, Negative Axillary Nodes and Estrogen Receptor Positive Tumors
CALGB #8961: RAS Mutations in Myelodysplasia
NSABP B-18: A “Unified” Trial to Compare Short Intensive Pre-Operative
Systemic Adriamycin Cyclo-phosphamide Therapy with Similar Therapy
Administered in Conventional Post-Operative Fashion
NSABP B-19: A Clinical Trial to Compare Sequential Methotrexate 5-Fluorouracil
with conventional CMF in Primary Breast Ca Patients with Negative Nodes &
Estrogen Receptor Negative Tumors
CALGB #8812: Didemin B for Multiple Myeloma, A Phase II Study
CALGB #8837: Hyperfractionation Radiotherapy & Chemotherapy in Limited
Stage Small Cell Lung Ca
CALGB #8951: Hydroxyurea + Cytosine Arabinoside for Relapsed or Refractory
Non-Hodgkins Lymphoma, A Phase II Study
CALGB #8841: Amonafide for Advanced Breast Ca, A Phase II Study
CALGB #8872: Randomized Study of Patient-Controlled Analgesia vs. Continuous
Iv Morphine for Severe Cancer Pain A Limited Access Cancer Control Study
-
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St. Luke’s Medical Center Cancer Research (continued)
CALGB #8933: Trimetrexate for Malignant Mesothelioma: Phase II
CALGB #8991: Phase III Chemotherapy of Disseminated Advanced Stage
Testicular Ca with Cisplatin + Etoposide with either Bleomycin or Ifosfamide
CALGB #8897: Phase III Comparison of Adjuvant Chemotherapy with or without
Endocrine Therapy in High-Risk, Node Negative Breast Ca Patients + a natural
history follow-up study in Low-Risk, Node Negative Patients
CALGB #8952: Treatment of Advanced Hodgkin’s Disease, A Randomized Phase III
Trial Comparing ABVD Vs. MOPP/ABV Hybrid
NSABP B-21: A Clinical Trial to Determine the Worth of Tamoxifen & the Worth
of Breast Radiation in the Management of Patients with Node-Negative Clinically
Occult, Invasive Breast Ca treated by Lumpectomy
Tumor Infiltrating Lymphocyte Therapy for Advance Melanoma and Renal
Renal Cancer (BRM 89-0001)
CALGB#8935: Tn-Modality Therapy for Stage lilA (N2) Non-Small Cell Lung Ca:
A Phase II Study Monoxide Intoxication
CALGB #8965: Utility of Flow Cytometric DNA Content and Reticulocyte
Analysis as Prognostic Indicators in Myelodysplastic Syndromes
Protocol No. STLMC BRM 890002: Alpha Interferon Pretreatment in IL-2/LAK
Therapy for Advanced Ca
CALGB #8622 (Re-activated) Monitoring Circulating Breast Cancer Associated
Antigens with the 15-3 Radioimmunoassay in Metastatic Breast Cancer
STLMC-BRM-90-01: IL-2/LAK Cell Therapy for Advanced
Uroepithelial Cancers
CALGB #8923: GM-CSF vs. Placebo During Remission Induction and
Mitoxantrone/ARA-C vs. ARA-C Intensification in Elderly Patients with Acute
Myeloid Leukemia
CALGB #8966: Laboratory Studies on Frozen Tumor Tissue of
Colorectal Carcinoma
Group C Protocol: Fludarabine Phosphate in Patients With Refractory
Chronic Lymphocytic Leukemia
URCC 2988P: Anxiety in Chemotherapy: Methods of Control
URCC C-02: Managing Chemotherapy Side Effects
URCC 2182M: Predictor of Relapse for Women with Stage I, II, or III Breast Cancer
URCC C-01: Coping with Radiation Treatment for Prostate Cancer
Comparison of the Early Bolus and Late Bolus Stages of Contrast Enhancement
in the Detection of Liver Metastases
CALGB #8971: A Dose Response Trial of Megestrol Acetate for the Treatment of
Cachexia in Patients with Lung or Colorectal Cancer
CALGB #8867: A Case Registry and Biological/Pathological Evaluation of Small
Cell Lung Cancer Presenting as a Solitary Pulmonary Nodule
CALGB #9061: Clinical Significance of Bcl-2 Rearranements in Lymphoma
Utilizing the Polymerase Chain Reaction
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St. Luke’s Medical Center Cancer Research (continued)
The Milwaukee Community Clinical Oncology Program Community Compliance
with Cancer Screening Recommendations A Prospective Randomized Study
Study
E302 CSF 39300: A Randomized, Double-Blinded, Placebo-Controlled
Trial No.
with Two Dosage Levels of Human Granulocyte-Macrophage Colony
Stimulating Factor (Recombinant, E. Coli) following Autologous Bone Marrow
Reconstitution for Lymphoma
Study No. C89-049-29: Double Blind Phase III Study of Patients with Intermediate
and High Grade Relapsing or Refractory Non-Hodjkin’s Lymphomas Utilizing
Intensive Chemotherapy with GM-CSF or Placebo
CALGB #9051: A Phase II Study of Etoposide, Vinblastine, Doxorubicin EVA,
and Subtotal Nodal Radiation in Poor Risk, Early Stage Hodgkin’s Disease
CALGB #9071: House Officers Training in Smoking Cessation
CALGB# 8911: Carboplatin for Multiple Myeloma A Phase II Study
CALGB# 8944: Intensive Doxorubicin, Surgery, CMF, and Radiation Therapy for
Stage III Breast Cancer A Study of Efficacy with Pharmacokinetic and Antigenic
Monitoring Phase II
CALGB# 9081: Intergroup Rectal Adjuvant Protocol: A Phase III Study
CALGB #9011: A Phase III Comparison of Fludarabine Phosphate vs. Chiorambucil
in Previously Untreated B-Cell Chronic Lymphocytic Leukemia
CALGB #9022: Intensive Post Remission Therapy with High Dose Cytocine
Arabinoside, Cyclophosphamide/Etoposide and Mitoxantrone/ Diaziquone in
Patients with Acute Myeloid Leukemia in First Remission
CALGB #9021: High Dose Cytarabine with or without Concurrent GM-CSF in the
Remission of Induction of Relapsed or Refractory Acute Myelogenous Leukemia
and Untreated Blast Crisis of Chronic Myelogenous Leukemia A Phase III Study
CALGB #9033: Oral vs. Intravenous Etoposide in Combination with Intravenous
Cisplatin in Extensive Small Cell Lung Cancer: Phase III Includes Pharmacology
Companion Protocol CALGB #9062
CALGB #9082: A Randomized Comparative Study of Adjuvant CAF Followed by
Standard CPA/cDDP/BCNU vs. Intensive CAPA/cDDP/BCNU Plus Autologous
Bone Marrow Support with Local Regional Radiation Therapy and Hormonal
Therapy for Patients with Stage Il/Ill Breast Cancer Involving 10 or more Lymph
Nodes
CUI-019003: A Randomized, Double-blind, Parallel Group Study of
of MAROGEN Sterile Powder (100 lU/kg and 200 lU/kg) vs. Placebo in the
Treatment of Anemia Associated with Chemotherapy
CALGB #9013: Subcutaneous Interferon Alpha-2b and Low Dose Cytarabine
(LODAC) in Previously Untreated Chronic Phase Chronic Myelogenous Leukemia-A
Phase II Study of Philadelphia Chromosome-Positive Patients
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St. Luke’s Cancer Confenrnces

Conferences are held on the second and fourth Monday of every
month at noon. This is a patient oriented, multi-disciplinary
cancer conference. For more information or questions, please call
649-6225.
This is a conference to discuss selected difficult head and neck
tumors from a multi-disciplinary approach. Conferences are held
on the first and third Monday of every month at noon. For more
information or questions, please call 649-3900.
February 16, 1989
THE BIOWGY BEHIND AND EFFECTIVENESS OF
NEUTRON THERAPY
Frank Hendrickson, M.D.
Chairman, Department of Radiation Therapy
Rush Presbyterian-St. Luke’s Medical Center
Chicago, IL
June 8, 1989
INTRALUMINAL RADIATION ThERAPY N ThE
BRONCHUS AND OTHER SITES: PALLIATION & CURE
Mark F Schray, M.D.
Assistant Professor of Oncology
Mayo Clinic
Consultant, Division of Radiation Oncology
Department of Oncology
Mayo Clinic
Rochester, MN
September 14, 1989
DIFFERENTIATED THYROID CANCER: FACTORS
INFWENCING PROGNOSIS AND THE IMPACT OF
THERAPY
Ernest L. Mazzaferri, M.D., F.A.C.P.
Professor of Internal Medicine & Physiology
Chairman of Internal Medicine
Ohio State University
Columbus, OH
October 26, 1989
HYPERCALCEMIA IN CANCER: IMPLICATIONS FOR
PATIENTS AND FOR HEALTh
Gordon J. Strewler, M.D.
Chief, Endrocrine Service
VA Medical Center
San Francisco, CA
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Tumor Board Conference

Head and Neck Tumor Conference

Security Savmgs & Loan Cancer
Lectureship Series 1989

Glossary

Stage Extent of disease determined at the time of diagnosis
and/or initial therapy.
IN SITU a tumor classified microscopically as in situ, noninvasive, pre-invasive, non-infiltrating, intraductal, intraepithelial
or intraepidermal.
LOCAL neoplasm restricted to the organ of origin, but may be
invasive or infiltrating within the organ of origin.
REGIONAL a tumor that has extended beyond the limits of
the organ of origin into (1) surrounding organs or tissues by
direct extension, (2) regional lymph nodes by metastasis, or a
combination of (1) and (2) and appears to have spread no
further.
DISTANT a neoplasm that has spread to other organs or
lymph nodes remote from the primary tumor.
-

-

-

-

-

First Course of Treatment The tumor directed treatments started
within the first four months after diagnosis.
ANALYTIC CASES Cases which are first diagnosed and/or
given their first course of treatment at St. Luke’s Medical Center.
NON-ANALYTIC CASES Cases which are seen at St. Luke’s
Medical Center after the first course of treatment and those
cases where the patient is diagnosed at autopsy.
-

-

-

Treatment
SURGERY the partial or total removal of the tumor excluding
biopsy.
RADIATION cancer-related beam and non-beam therapy (non
beam includes radium, cesium and radioactive isotopes).
CHEMOTHERAPY treatment of cancer using drugs.
COMBINED THERAPY refers to any combination of surgery,
radiation, chemotherapy, hormone therapy or other therapy
administered jointly as a single course of treatment.
DIAGNOSTIC ONLY cancer-related treatment not given; this
may occur for many reasons; for example, patient refused
treatment, diagnosed at autopsy, or the patient’s general
condition is unsatisfactory for treatment.
-

-

-

-

-
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